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Quieting the Catecholamine Storm: A Preoperative Approach to Managing the Pheochromocytoma Patient
R.S. Schreiner, and H. Zhang

Department of Internal Medicine, Lehigh Valley Health Network, Allentown, PA

Introduction

Case Report

The Who: A pheochromocytoma, a rare
catecholamine-secreting tumor derived
from chromaffin cells. Catecholamines
released from the tumor stimulate both
alpha- and beta-adrenergic receptors.

A 33-year-old Asian female presented to the emergency department with headaches, flushing, palpitations, diaphoresis,
and insomnia. She was tachycardiac to 144 and hypertensive to 220/118. She had no previous history of hypertension.
Orthostatic measurements were also positive as her standing blood pressure was 89/61. Creatinine and troponins were mildly
elevated. EKG showed sinus tachycardia with 1st-degree AV block and right axis deviation. An abdominal CT revealed a 6
cm right adrenal mass contiguous with the liver and superior pole of the kidney. 24-hour urine catecholamine measurement
revealed markedly elevated epinephrine and norepinephrine levels, confirming the diagnosis of pheochromocytoma. Surgery,
nephrology, and endocrinology services were consulted. The patient was admitted to the intensive care unit due to the labile
nature of her blood pressure. Treatment was initiated with phenoxybenzamine 10mg BID along with maintenance intravenous
fluids of NSS 100 cc/hr. Her blood pressure remained labile on day two, with 74-179 systolic and 65-140 diastolic. She
was still tachycardic to 110. Fluids were increased to 150cc/hr. On day three, the phenoxybenzamine dose was doubled to
20mg BID. Her tachycardia did not resolve and on day four, metoprolol 12.5mg BID was added. The patient’s blood pressure
normalized and remained stable. She was asymptomatic, creatinine returned to baseline, and she was transferred to lowlevel monitoring. Her blood pressure was stable at 90-110 systolic and 50-70 diastolic. After achieving hemodynamic stability,
surgery was scheduled. On day 5, metoprolol was doubled to 25mg BID. This regimen was continued until day 9 when
metoprolol was taken back down to 12.5mg BID in preparation for surgery. This treatment regimen was continued for 1 more
day before a successful laparoscopic right adrenalectomy.

The Where: Typically an adrenal tumor,
also associated with syndromes including
von Hippel-Lindau (VHL) syndrome,
multiple endocrine neoplasia type 2 (MEN
2), and neurofibromatosis type I (NF1).
The What: Secretes epinephrine and
norepinephrine which can precipitate
life-threatening hypertensive crises
and cardiac arrhythmias. About 10%
are malignant, which is defined as the
presence of metastases.

Discussion

The How: Surgical resection remains
the standard treatment of choice.
The Why: A preoperative
approach to the management of the
pheochromocytoma patient has yet to
be standardized. Here we provide an
anecdotal preoperative outline to the
management of a hemodynamically
unstable patient suffering from
pheochromocytoma.

Preoperative management of the pheochromocytoma
patient is not well elucidated. This case describes
a successful sequence of steps taken to ensure
preoperative hemodynamic stability.
•	If beta-blockers are used alone, unopposed alphamediated vasoconstriction will occur, thus exacerbating
hypertension to dangerous levels. Alpha-blockade
should occur first.
•	Volume re-expansion is important. Since accelerated
hypertension will cause pressure natriuresis, large volume
re-expansion with normal saline solution was achieved.
However, volume balance should be kept even.
•	It is important to initiate beta-blockage to stabilize
heart rate, which may lead to tachyarrhythmias if
uncontrolled.
•	Beta-blockade was then titrated down the day
before surgery to avoid protracted hypotension as
vasodilation would follow pheochromocytoma
removal.
•	With the concerted efforts of multiple teams including
endocrinology, nephrology, critical care medicine,
and surgery, the pheochromocytoma patient may be
appropriately cared for preoperatively.
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Image 1.

Transverse view of CT scan showing
large right suprarenalmass contiguous
with the liver. The mass was a
pheochromocytoma after confirmation
by elevated 24-hour urinary
metanephrines.

Image 2.

Coronal view of CT
scan showing a 6 cm
pheochromocytoma.

Image 3.

Timeline of preoperative treatment before successful
removal of a pheochromocytoma.
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